Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.

Panjwani N, Yoo CH, Wang E, Khodadoust MS, Kim YH, Hoppe RT, Hiniker SM.

J Dermatolog Treat. 2019 Jun 10:1-5. doi: 10.1080/09546634.2019.1628913. [Epub ahead of print]

PMID:
31179774
2.

Determining cell type abundance and expression from bulk tissues with digital cytometry.

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA.

Nat Biotechnol. 2019 May 6. doi: 10.1038/s41587-019-0114-2. [Epub ahead of print]

PMID:
31061481
3.

Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs.

Obeid JP, Gutkin PM, Lewis J, Skinner L, Wang EB, Khodadoust MS, Kim YH, Weng WK, Hoppe RT, Hiniker SM.

Pract Radiat Oncol. 2019 Mar 2. pii: S1879-8500(19)30070-0. doi: 10.1016/j.prro.2019.02.016. [Epub ahead of print] No abstract available.

PMID:
30836188
4.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108
5.

B-cell lymphomas present immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA.

Blood. 2019 Feb 21;133(8):878-881. doi: 10.1182/blood-2018-06-845156. Epub 2018 Dec 13. No abstract available.

6.

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.

PMID:
30125215
7.

Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.

Erdrich J, Schaberg KB, Khodadoust MS, Zhou L, Shelton AA, Visser BC, Ford JM, Alizadeh AA, Quake SR, Kunz PL, Beausang JF.

Cold Spring Harb Mol Case Stud. 2018 Oct 1;4(5). pii: a003004. doi: 10.1101/mcs.a003004. Print 2018 Oct.

8.

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.

Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng WK, Kim YH.

JAMA Dermatol. 2018 Jun 1;154(6):728-730. doi: 10.1001/jamadermatol.2018.0884. No abstract available.

9.

Transcript-indexed ATAC-seq for precision immune profiling.

Satpathy AT, Saligrama N, Buenrostro JD, Wei Y, Wu B, Rubin AJ, Granja JM, Lareau CA, Li R, Qi Y, Parker KR, Mumbach MR, Serratelli WS, Gennert DG, Schep AN, Corces MR, Khodadoust MS, Kim YH, Khavari PA, Greenleaf WJ, Davis MM, Chang HY.

Nat Med. 2018 May;24(5):580-590. doi: 10.1038/s41591-018-0008-8. Epub 2018 Apr 23.

10.

T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.

Olsson N, Schultz LM, Zhang L, Khodadoust MS, Narayan R, Czerwinski DK, Levy R, Elias JE.

Proteomics. 2018 Jun;18(12):e1700410. doi: 10.1002/pmic.201700410. Epub 2018 Apr 18.

11.

Profiling Tumor Infiltrating Immune Cells with CIBERSORT.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA.

Methods Mol Biol. 2018;1711:243-259. doi: 10.1007/978-1-4939-7493-1_12.

12.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M.

Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.

13.

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA.

Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22.

14.

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

Khodadoust MS, Luo B, Medeiros BC, Johnson RC, Ewalt MD, Schalkwyk AS, Bangs CD, Cherry AM, Arai S, Arber DA, Zehnder JL, Gotlib J.

Leukemia. 2016 Apr;30(4):947-50. doi: 10.1038/leu.2015.136. Epub 2015 Jun 9. No abstract available.

15.

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, Advani RH, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):99-106. doi: 10.1016/j.ijrobp.2015.01.039.

PMID:
25863757
16.

Tumor antigen discovery through translation of the cancer genome.

Khodadoust MS, Alizadeh AA.

Immunol Res. 2014 May;58(2-3):292-9. doi: 10.1007/s12026-014-8505-4. Review.

PMID:
24718952
17.

The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.

Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R, Markovitz DM.

Genes Dev. 2011 Apr 1;25(7):673-8. doi: 10.1101/gad.2036411.

18.

DEK expression in melanocytic lesions.

Kappes F, Khodadoust MS, Yu L, Kim DS, Fullen DR, Markovitz DM, Ma L.

Hum Pathol. 2011 Jul;42(7):932-8. doi: 10.1016/j.humpath.2010.10.022. Epub 2011 Feb 11.

19.

Melanoma proliferation and chemoresistance controlled by the DEK oncogene.

Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS.

Cancer Res. 2009 Aug 15;69(16):6405-13. doi: 10.1158/0008-5472.CAN-09-1063.

20.

DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.

Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM, Ferrando-May E.

Mol Cell Biol. 2008 May;28(10):3245-57. doi: 10.1128/MCB.01921-07. Epub 2008 Mar 10.

21.

The DEK nuclear autoantigen is a secreted chemotactic factor.

Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D, Petruzzelli L, Adams BS, Markovitz DM.

Mol Cell Biol. 2006 Dec;26(24):9484-96. Epub 2006 Oct 9.

22.

p300/CBP-associated factor drives DEK into interchromatin granule clusters.

Cleary J, Sitwala KV, Khodadoust MS, Kwok RP, Mor-Vaknin N, Cebrat M, Cole PA, Markovitz DM.

J Biol Chem. 2005 Sep 9;280(36):31760-7. Epub 2005 Jun 28.

Supplemental Content

Loading ...
Support Center